Compare RXST & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXST | IMRX |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.3M | 366.1M |
| IPO Year | 2021 | 2021 |
| Metric | RXST | IMRX |
|---|---|---|
| Price | $8.39 | $4.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $11.40 | ★ $17.20 |
| AVG Volume (30 Days) | 1.3M | ★ 2.6M |
| Earning Date | 02-24-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,085,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.75 | N/A |
| 52 Week Low | $6.32 | $1.10 |
| 52 Week High | $34.70 | $10.08 |
| Indicator | RXST | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 41.35 |
| Support Level | $7.73 | $4.51 |
| Resistance Level | $9.45 | $5.02 |
| Average True Range (ATR) | 0.52 | 0.35 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 16.56 | 23.33 |
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.